A fatal case of atypical intracerebral hemorrhage in the left temporal lobe occurred in a 35-year-old pregnant woman twelve days following her first dose of the ChAdOx1 nCoV-19 vaccine. Reported in medical literature via Cureus and PMC, the incident highlights vaccine-induced thrombotic thrombocytopenia as a rare but severe immune-mediated complication.
In Plain English: The Clinical Takeaway
VITT Mechanism: Vaccine-induced thrombotic thrombocytopenia occurs when the immune system forms antibodies against platelet factor 4, resembling heparin-induced thrombocytopenia without prior heparin exposure.
Key Clinical Signs: Patients with VITT typically present with thrombocytopenia (low blood platelets) and thrombosis at unusual sites, such as cerebral venous sinus thrombosis.
Pregnancy Risks: Pregnant patients with COVID-19 are more likely to die or need intensive care compared with non-pregnant persons of reproductive age.
Pathology and Clinical Presentation of VITT
The ChAdOx1 nCoV-19 vaccine, developed by Oxford-AstraZeneca, utilizes a replication-deficient chimpanzee adenoviral vector containing the SARS-CoV-2 structural surface glycoprotein spike antigen gene. While clinical trials involving 23,848 participants detected no signal for increased thrombotic events, widespread global administration exposed a rare syndrome designated as vaccine-induced thrombotic thrombocytopenia (VITT).
The underlying mechanism of VITT involves immune-driven reactions where platelet-activating antibodies recognize multimolecular complexes formed by cationic platelet factor 4 (PF4) and anionic heparin. This clinical presentation resembles heparin-induced thrombocytopenia (HIT), though classically there is no heparin exposure in VITT. Cerebral venous sinus thrombosis (CVST) appears in 72% of the VITT reports, marking it as a life-threatening event.
Case Analysis of the 35-Year-Old Patient
In the documented case, a 35-year-old white pregnant woman at 23 weeks gestation presented with controlled hypothyroidism due to Hashimoto’s disease and normal platelet counts. She received her first dose of the ChAdOx1 nCoV-19 vaccine in late April 2021. Following minor initial symptoms including malaise, chills, tremors, and a generalized skin rash on day two, she developed a urinary tract infection caused by Morganella morganii treated with trimethoprim-sulfamethoxazole on day three, alongside a platelet count of 148,000/mm3.
By day seven, she experienced headache, nausea, nonspecific malaise, polaciuria, and pain in the lower limbs and hips. Despite having 121,000/mm3 platelets, she received analgesics and discharge from an obstetric emergency room. Her headaches and bilateral leg pain persisted and worsened until day eleven, when she reported a severe headache located in the left maxillary region. On day twelve, she was admitted with platelet counts of 33,000/mm3 and an excruciating headache, and an acute intraparenchymal hematoma measuring approximately 10.1×5.4×5.5 cm in the left cerebral hemisphere, resulting in a fatal outcome.
| Timeline Post-Vaccination | Clinical Symptoms | Laboratory Findings & Interventions |
|---|---|---|
| Day 0 | Administered first dose of ChAdOx1 nCoV-19 vaccine. | Prenatal follow-up at 23 weeks gestation; controlled hypothyroidism. |
| Days 1–2 | Malaise, chills, tremors, and generalized skin rash. | Spontaneous resolution of cutaneous symptoms. |
| Day 3 | Asymptomatic for neurological issues; routine prenatal check. | Platelet count: 148,000/mm3; treated for urinary tract infection. |
| Days 7–10 | Persistent headache, nausea, lower limb and hip pain. | Platelet count: 121,000/mm3; discharged with analgesics. |
| Days 11–12 | Severe maxillary headache, rapid neurological decline, coma. | Platelet count dropped to 33,000/mm3; CT confirmed large temporal hematoma. |
Regulatory Context and Global Safety Monitoring
Research into adenoviral vector platforms continues to inform ongoing vaccine safety protocols.
References
Disclaimer: This article is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.
